索拉非尼
化学
肝细胞癌
谷胱甘肽
药理学
生物利用度
新陈代谢
癌症研究
细胞生长
药物代谢
六氯环己烷
肝癌
还原酶
谷胱甘肽还原酶
谷胱甘肽代谢
药品
细胞色素P450
生物化学
赫尔格
代谢稳定性
阿霉素
平衡
微粒体
细胞凋亡
氧化应激
毒性
细胞培养
作者
Zhigang An,Hongyun Zou,Yuqi Sun,Xinyu Deng,Xinjue Ping,Zixuan Li,Yingxin Li,Qi Hu,Kaiyan Long,Xi Zhang,Yan Peng,Hanxuan Mo,Ying Peng,Heng Yang,Weifan Jiang,Yanhong Luo,Zhen Wang,Linsheng Zhuo
标识
DOI:10.1021/acs.jmedchem.6c00802
摘要
Abstract Sorafenib offers limited benefit in hepatocellular carcinoma (HCC). In this study, we designed and synthesized a series of novel corydamine derivatives and identified 8g as a lead compound with anti-HCC activity comparable to sorafenib. Mechanistic studies suggest that 8g targets glutathione reductase (GR), disrupting glutathione metabolism and NADPH homeostasis and weakening tumor redox defenses. Notably, the combination of 8g and sorafenib markedly enhanced ROS generation, inhibited HCC cell migration and invasion, and induced G2/M arrest and apoptosis, demonstrating strong synergistic anticancer activity. In addition, 8g showed favorable druggability, including good metabolic stability in human liver microsomes (T1/2 > 5 h), low hERG inhibition (IC50 > 50 μM), and high oral bioavailability (84.9%). In a Huh7 xenograft model, the combination achieved 61.0% tumor growth inhibition, significantly outperforming sorafenib alone (29.7%). These findings propose a redox-targeting strategy to sensitize HCC to sorafenib and highlight 8g as a promising anti-HCC lead.
科研通智能强力驱动
Strongly Powered by AbleSci AI